The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5
2012, Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy, PLoS One, 7, e29849, 10.1371/journal.pone.0029849
Ray, 2010, Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants, Arch Intern Med, 170, 1024, 10.1001/archinternmed.2010.182
Taylor, 2011, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, 1
Redberg, 2011, Editor's Note—to make the case—evidence is required: comment on “Making the case for selective use of statins in the primary prevention setting”, Arch Intern Med, 171, 1594, 10.1001/archinternmed.2011.409
Kerr, 2009, Should the first priority in cardiovascular risk management be those with prior cardiovascular disease?, Heart, 95, 125, 10.1136/hrt.2007.140905
1995, Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens, Am J Cardiol, 75, 1130, 10.1016/S0002-9149(99)80744-9
2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1
de Lemos, 2004, Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial, JAMA, 292, 1307, 10.1001/jama.292.11.1307
Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583
Pedersen, 2005, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial, JAMA, 294, 2437, 10.1001/jama.294.19.2437
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001
1997, The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts, N Engl J Med, 336, 153, 10.1056/NEJM199701163360301
Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, 1615, 10.1001/jama.279.20.1615
1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902
2000, Ital Heart J, 1, 810
Serruys, 2002, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial, JAMA, 287, 3215, 10.1001/jama.287.24.3215
2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3
Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X
2002, Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT), JAMA, 288, 2998, 10.1001/jama.288.23.2998
Holdaas, 2003, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial, Lancet, 361, 2024, 10.1016/S0140-6736(03)13638-0
Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5
Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401
Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 353, 238, 10.1056/NEJMoa043545
Knopp, 2006, Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN), Diabetes Care, 29, 1478, 10.2337/dc05-2415
Koren, 2004, Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study, J Am Coll Cardiol, 44, 1772
Nakamura, 2006, Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial, Lancet, 368, 1155, 10.1016/S0140-6736(06)69472-5
Fellstrom, 2009, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis, N Engl J Med, 360, 1395, 10.1056/NEJMoa0810177
Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646
Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201
2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1231, 10.1016/S0140-6736(08)61240-4
LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461
2010, Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial, Lancet, 376, 1658, 10.1016/S0140-6736(10)60310-8
Amarenco, 2006, High-dose atorvastatin after stroke or transient ischemic attack, N Engl J Med, 355, 549, 10.1056/NEJMoa061894
Athyros, 2002, Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study, Curr Med Res Opin, 18, 220, 10.1185/030079902125000787
Armitage, 2007, The safety of statins in clinical practice, Lancet, 370, 1781, 10.1016/S0140-6736(07)60716-8
Davidson, 2007, Safety of aggressive lipid management, J Am Coll Cardiol, 49, 1753, 10.1016/j.jacc.2007.01.067
Cheung, 2010, Is intensive LDL-cholesterol lowering beneficial and safe?, Lancet, 376, 1622, 10.1016/S0140-6736(10)61545-0
Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6
Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis, JAMA, 305, 2556, 10.1001/jama.2011.860
2010, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies, Lancet, 375, 2215, 10.1016/S0140-6736(10)60484-9
Strandberg, 2004, Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S), Lancet, 364, 771, 10.1016/S0140-6736(04)16936-5
2002, Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up, Lancet, 359, 1379, 10.1016/S0140-6736(02)08351-4
Ford, 2007, Long-term follow-up of the West of Scotland Coronary Prevention Study, N Engl J Med, 357, 1477, 10.1056/NEJMoa065994
2011, Effects on 11 year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals, Lancet, 378, 2013, 10.1016/S0140-6736(11)61125-2
Grundy, 2004, Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E
2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486
Reiner, 2011, ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158
Cooper, 2008
2006, Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people, BMJ, 333, 1145, 10.1136/bmj.38993.731725.BE
Lazar, 2011, Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era, Circulation, 124, 146, 10.1161/CIRCULATIONAHA.110.986349